Arrogene, Inc. logo — Innovative cancer treatment technology delivering advanced n...

Arrogene, Inc.

Innovative cancer treatment technology delivering advanced nano agents to target tumors, enhancing patient outcomes and offering personalized care solutions.

Founded 2007 1 employees Venture round Total: $7.90M Biotechnology, Health Care

General Information

Company Name Arrogene, Inc.
Founded Year 2007
Founders / Decision Makers
Team member Team member
Employees 1
Industries Biotechnology, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Arrogene, Inc.. To contact Arrogene, Inc., visit arrogene.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Arrogene, Inc. compare?

A PDF of Arrogene, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Arrogene, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Arrogene, Inc.

Arrogene, Inc. is a biotechnology company founded in 2007 with a focus on developing innovative cancer treatment technologies. The company's slogan "Innovative cancer treatment technology delivering advanced nano agents to target tumors, enhancing patient outcomes and offering personalized care solutions" summarizes their approach. Arrogene's pioneering advancements involve crafting nano agents capable of transporting peptide, protein, and oligonucleotide therapeutics through the blood-brain barrier, providing a specialized approach in nano-medicine. Their technology stands out for effectively delivering a combination of tumor inhibitors or imaging agents, catering to various cancer types. The last notable milestone for Arrogene was a $3.23M Venture Round investment on 08 May 2018. This funding signifies a vote of confidence in the company's potential to make a significant impact in the biotechnology and healthcare industries.

Business keywords: cancer treatment, nano agents, tumor inhibitors, imaging agents, peptide therapeutics, protein therapeutics, oligonucleotide therapeutics, blood-brain barrier, personalized care solutions, nanomedicine, precision medicine, oncology technology, targeted therapy, patient outcomes

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $3.23M -
08 May 2018
Debt Financing $750.00K -
18 Mar 2016
Debt Financing $250.00K -
07 Jan 2015
Debt Financing $170.00K -
07 Mar 2014
Venture Round $2.27M -
12 Jun 2013
Debt Financing $496.55K -
16 Mar 2011
Venture Round $726.55K -
12 Oct 2010

Arrogene, Inc. Alternatives & Competitors

View All Alternatives
Arrogene, Inc. vs
Cvergenx
Cvergenx United States

An innovative leader in cancer molecular diagnostics, delivering personalized radiation therapy to e...

Seed
2 employees
Biotechnology, Health Care
Arrogene, Inc. vs

成为国际一流、品质卓越的放射性药物公司 Global pioneer in radiopharmaceuticals and commitment to qual...

Series A
3 employees
Biopharma, Biotechnology
Arrogene, Inc. vs

Dedicated to developing effective and novel targeted treatments for cancer.

Grant
12 employees
Biopharma, Biotechnology

FAQ About Arrogene, Inc.

Innovative cancer treatment technology delivering advanced nano agents to target tumors, enhancing patient outcomes and offering personalized care solutions.
Arrogene, Inc. was founded in 2007.
Arrogene, Inc. operates in Biotechnology and Health Care. Its work centres on cancer treatment, nano agents, tumor inhibitors and imaging agents.
Arrogene, Inc. has approximately 1 employees.
Arrogene, Inc. has completed 7 funding rounds, raising a total of $7.90M. The latest funding stage is Venture round.
Top alternatives and competitors to Arrogene, Inc. include Cvergenx, BoomRay Pharmaceuticals, Soricimed Biopharma Inc., ViewRay, Inc., Genus Oncology LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arrogene, Inc. and Cvergenx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Arrogene, Inc., https://bouncewatch.com/company/arrogene, updated 24 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes